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rothelial plaques consist of four major uroplakins
(Ia, Ib, II, and III) that form two-dimensional crystals
covering the apical surface of urothelium, and pro-
vide unique opportunities for studying membrane protein
assembly. Here, we describe a novel 35-kD urothelial plaque-
associated glycoprotein that is closely related to uroplakin III:
they have a similar overall type 1 transmembrane topology;
their amino acid sequences are 34% identical; they share
an extracellular juxtamembrane stretch of 19 amino acids;
their exit from the ER requires their forming a heterodimer
with uroplakin Ib, but not with any other uroplakins; and
UPIII-knockout leads to p35 up-regulation, possibly as a
U
 
compensatory mechanism. Interestingly, p35 contains a
stretch of 80 amino acid residues homologous to a hypo-
thetical human DNA mismatch repair enzyme-related
protein. Human p35 gene is mapped to chromosome
7q11.23 near the telomeric duplicated region of Williams-
Beuren syndrome, a developmental disorder affecting
multiple organs including the urinary tract. These results
indicate that p35 (uroplakin IIIb) is a urothelial differentiation
product structurally and functionally related to uroplakin
III, and that p35–UPIb interaction in the ER is an important
early step in urothelial plaque assembly.
 
Introduction
 
The cell surface plays a key role in mediating the interactions
between a cell and its environment. Thus, membrane proteins
serve as receptors for many extracellular signals provided by
growth factors, hormones, ECM, and neighboring cells. Cell
surface proteins also perform specialized cellular functions
including absorption, secretion, and the formation of a
permeability barrier. Many of these cell surface molecules
are complexes of several subunits that must be assembled,
processed, and targeted to the proper domains of the cell
surface in order to function. Defects in delivering functional
membrane proteins to the cell surface can have major biological
consequences, including compromised cellular functions or
even uncontrolled cell growth leading to neoplasm. There-
fore, it is important to better understand membrane protein
assembly and targeting.
Urothelial plaques (also known as asymmetric unit mem-
branes [AUM]) are structurally unique in that they consist
of 16-nm protein particles arranged hexagonally, forming
two-dimensional crystals (Hicks and Ketterer, 1969; Vergara
et al., 1969; Brisson and Wade, 1983; Walz et al., 1995; Kachar
et al., 1999). These plaques represent the major differentiation
products of mammalian urothelia; thus, they can be readily
isolated with an extraordinary yield of 10–20 mg of highly
purified two-dimensional crystals from 
 
 
 
100 bovine bladders
within 2 d (Wu et al., 1990). Consistent with their crystalline
structure, urothelial plaques have a relatively simple protein
composition consisting of four known uroplakin (UP)*
subunits, i.e., UPIa (27 kD), UPIb (28 kD), UPII (15 kD),
and UPIII (47 kD; Wu and Sun, 1993; Lin et al., 1994; Yu
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et al., 1994; Sun et al., 1999). Cultured urothelial cells form
stratified cell layers and continue to synthesize uroplakins,
which, however, fail to assemble into two-dimensional crys-
tals, thus providing unique opportunities to study the regula-
tion of membrane assembly (Surya et al., 1990). Uroplakins Ia
and Ib have four transmembrane domains, are 
 
 
 
40% identi-
cal in their amino acid sequences, and belong to the “tetraspa-
nin” gene family that contains many leukocyte- and cancer-
associated cell surface proteins including CD9, CD37, CD53,
and CD63 (Yu et al., 1994; Maecker et al., 1997; Hemler,
2001). On the other hand, uroplakins II and III have only a
single transmembrane domain. UPII is synthesized as a pre-
cursor containing a signal peptide and a pro-sequence; the ma-
ture protein anchors into the membrane via its COOH-termi-
nal transmembrane domain (Lin et al., 1994). Uroplakin III
also has a signal peptide and a single transmembrane domain
that separates a long (
 
 
 
200 amino acids) extracellular from
a short (
 
 
 
50 amino acids) intracellular domain (Wu and
Sun, 1993). Interestingly, the two tetraspanin-type uroplakins
(UPIa and UPIb) are cross-linked selectively to UPII and
UPIII, respectively, suggesting the existence of two separate
uroplakin pairs (Wu et al., 1995). Together, these results indi-
cate that urothelial plaque provides an excellent model for
studying membrane protein assembly (Sun et al., 1999).
To understand the assembly of urothelial plaques, it is cru-
cial to fully characterize all the protein subunits of the plaques,
including some minor components that can potentially play
regulatory functions. In this regard, it should be noted that
highly purified bovine urothelial plaques contain, in addition
to the four known uroplakins that account for 
 
 
 
90% of the
total protein mass, another protein of 35 kD (p35) that re-
mained uncharacterized (Liang et al., 1999). In this paper, we
show that p35 represents a novel urothelial differentiation
marker that is homologous to uroplakin III in sequence and
transmembrane topography. Interestingly, p35 also shares a
stretch of 80 amino acid residues (78–157) that is 
 
 
 
90%
identical to a portion of a human DNA mismatch repair
(MMR) enzyme-related PMSR6 protein (Horii et al., 1994;
Nicolaides et al., 1995). The human p35 gene is mapped to
chromosome 7q11.23 near a region that is frequently deleted
in patients with the Williams-Beuren syndrome (WBS; On-
line Mendelian Inheritance in Man [OMIM], 2002, MIM
no. 194050, available at http://www.ncbi.nlm.nih.gov/omim;
Francke, 1999), a developmental disorder affecting multiple
systems including the urinary tract (Babbitt et al., 1979; Mor-
ris et al., 1990; Francke, 1999).
 
Results
 
P35 is highly conserved during mammalian evolution
 
As mentioned earlier, highly purified bovine urothelial
plaques contained a well-resolved p35 band (Fig. 1 a, lane 1)
that we cloned by partial sequencing, RT-PCR (Fig. 1 b, lane
1), and cDNA library screening. The cDNA-deduced amino
acid sequence of bovine p35 (Fig. 1 c) was found to be 
 
 
 
90%
identical to those of human and mouse p35, which we also
cloned, indicating a high degree of evolutionary conservation
(Figs. 1 c and 2 a). Interestingly, the amino acid sequence of
bovine p35 shared several features with uroplakin III. The
core proteins of p35 and UPIII were both 
 
 
 
30 kD in size and
were 34% identical (Fig. 2 b), and they adopted a similar
transmembrane topography. Both p35 and UPIII were type
1 transmembrane proteins with a signal peptide and a single
transmembrane domain (Fig. 2, a, b, and d). Both had a long
NH
 
2
 
-terminal extracellular domain (
 
 
 
200 amino acid resi-
dues) harboring several 
 
N
 
-glycosylation sites (one for p35 and
4 for UPIII), and a short COOH-terminal cytoplasmic do-
main (
 
 
 
50 amino acids; Fig. 2, b and d). In addition, both
possessed a domain of 19 amino acid residues (190-IDTW-
PGRRSGDMIIITSIL-208 for p35; 197-IDTWPGRRSG-
GMIVITSIL-215 for uroplakin III) that was located in a
juxtamembrane position immediately NH
 
2
 
-terminal to the
transmembrane domain (Fig. 2, b, c, and d). However, the
p35 was unique in that its NH
 
2
 
-terminal extracellular domain
contained a stretch of 80 amino acid residues (78–157) that
were 
 
 
 
74% identical and 
 
 
 
83% similar to a hypothetical hu-
man DNA MMR enzyme-related protein (the “PMSR6”
gene; Figs. 1 c and 2 d; Horii et al., 1994; Nicolaides et al.,
1995). RT-PCR using primers corresponding to the PMSR6-
and UPIII-related regions yielded the expected p35 PCR
products, thus proving the colinear existence of these two do-
mains in bovine p35 (Fig. 2 a and unpublished data).
 
P35 expression is urothelial-specific 
and differentiation-dependent
 
Northern and PCR analyses showed that p35 expression was
urothelium-specific in both bovine (Fig. 3, compare a with b
Figure 1. Isolation and characterization 
of the bovine p35 cDNA. (a) SDS-PAGE 
analysis of purified bovine urothelial 
plaques (lane 1) showing the presence of a 
35-kD protein (p35) in addition to the four 
known uroplakins (Ia, Ib, II, and III). The 
electrophoretically purified p35 protein 
yielded five partial sequences by mass 
spectrometry: (1) (I/L)D(I/L)(I/L)PYTPR; 
(2) QNPQT(I/L)AE(I/L)HNTR; 
(3) DAGSS(I/L)AD(I/L)HQPR; 
(4) YMTNP(I/L)TM; and 
(5) SSYNAP(I/L)PGNGAVTK. M denotes 
molecular mass markers (from top to bottom; 66, 45, 36, 29, 24, 20, 
and 14 kD). Asterisk marks an uncharacterized 18-kD band. 
(b) Agarose gel analysis showing a 186-bp PCR fragment of p35 
generated using degenerate primers designed according to two partial 
protein sequences of p35 (QNPQTLAE and DAGCLADLHQPR; 
lane 1, arrow), and a control PCR products of bovine uroplakin III 
(lane 2). M denotes DNA size markers. (c) The cDNA-deduced 
amino acid sequence of bovine p35. The 186-bp PCR product was 
used to screen a bovine urothelial cDNA library yielding an  2.4-kb 
full-length cDNA that contained a 198-bp 5 -untranslated 
sequence, a single open reading frame of 1,038-bp encoding 
279-amino acids that can account for all five partial sequences from 
mass spectrometry, and 1,343 bp of 3 -untranslated region. The 
5  upstream sequence contained multiple stop codons, and the 
translational initiation site conformed to the consensus sequences 
(Kozak, 1984, 2000), whereas the 3 -untranslated region contained 
a polyadenylation signal with a poly(A)
  tail (not depicted). Arrowhead 
marks the boundary of a possible signal peptide. Dotted underline 
denotes a stretch of 80 amino acid residues that are homologous to 
the NH2-terminal region of a hypothetical human DNA MMR 
enzyme-related protein hPMSR6. Box denotes an amino acid 
sequence highly conserved in p35 and uroplakin III. Thick bar 
marks the hypothetical transmembrane domain. 
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and c) and mouse (Fig. 3, compare d with e and f). To localize
the p35 protein, we generated rabbit antisera against three syn-
thetic peptides of p35. All these antisera recognized the p35
Figure 2. The amino acid sequence of p35 is conserved and is highly 
homologous to uroplakin III. (a) cDNA-deduced amino acid 
sequences of p35 from human (H), mouse (M), and bovine (B). Arrow-
head marks the end of signal peptide. HPMSR6 and CD denote the 
hPMSR6 homologous domain, and the conserved domain shared by 
p35 and uroplakin III (and uroplakin II), respectively. Thick bar denotes 
the transmembrane domain. (b) Alignment of bovine p35 and 
uroplakin III. Dots were introduced to maximize the alignment. 
Asterisks indicate identity. Note the significant sequence homology 
between the two proteins, particularly the CD. (c) A part of the CD is 
also shared by uroplakin II (underlined). (d) Overall structure of bovine 
p35 and uroplakin III. Note the similarities in their size, and the 
location of the transmembrane and CDs. SP denotes signal peptide.
Figure 3. Urothelial specificity of p35 
in bovine and mouse. For bovine tissues 
(a–c), 20  g total RNA from 11 tissues 
was separated on a formaldehyde gel, 
transferred to a nylon membrane, and 
probed with (a) p35 cDNA, (b)   actin 
cDNA, (c) an ethidium bromide (EB)–
stained gel. For mouse tissues, cDNAs 
from various tissues were used to 
amplify (d) p35, (e) uroplakin III, or 
(f) glyceraldehyde phosphate dehydro-
genase as a loading control. Tissues 
analyzed include bladder (B), brain 
(Br; forebrain [FB] and rear brain [RB]), 
colon (C), esophagus (E), heart (H), intestine (I), kidney (K), liver (L), 
lung (Lu), skeletal muscle (M), spleen (S), and stomach (St).
 
Figure 4.
 
The urothelial differentiation-dependent expression of 
p35.
 
 (a) A rabbit antiserum was generated to a synthetic peptide 
(positions 268–279 in the cDNA-deduced protein sequence of p35) 
and used to immunoblot total bovine urothelial proteins (lane 2), 
total membrane proteins (lane 3), purified bovine urothelial plaque 
proteins (lane 4), and purified mouse urothelial plaque proteins 
(lane 5). Lanes M and 1 denote molecular mass markers (M; from 
top to bottom: 66, 45, 36, 29, 24, 20, and 15 kD) and total bovine 
urothelial plaque proteins (1). Note the strong reaction of this antibody 
to p35 of purified urothelial plaques, and the mono-specificity of the 
antiserum in total urothelial extracts. (b and c) Deglycosylation of 
p35 (b) and uroplakin III (c). Total bovine urothelial plaque proteins 
(1); same proteins after overnight incubation in the deglycosylation 
buffer (lane 2); same proteins treated with Endo H (lane 3) or Endo F 
(lane 4). The proteins were electrophoretically separated, transferred 
to nylon membranes, and blotted with antibodies to p35 (b) or 
uroplakin III (c). Note the shift of both p35 and uroplakin III to 
 
 
 
30 kD, 
indicating similar core protein size and suggesting the presence of a 
complex N-linked oligosaccharide. The high molecular weight band 
represents dimer formation. (d–g) Immunolocalization of p35 (d and 
f) and uroplakin III (e and g) in bovine (d and e) and mouse (f and g) 
urothelium. Note the association with p35 and UPIII with superficial 
umbrella cells in bovine urothelium, and with suprabasal cells in 
mouse urothelium. (h) Differentiation-dependent expression of p35 
and UPIII in cultured bovine urothelial cells. (lane 1) mouse 3T3 
cells, (lane 2) bovine bladder fibroblasts, cultured bovine bladder 
epithelial cells at (lane 3) 50% confluence, (lane 4) 100% confluence, 
(lane 5) 3-d post confluence (pc) (lane 6) 6-d pc, (lane 7) 9-d pc, 
(lane 8) in vivo bovine bladder epithelium, and (lane 9) bovine ureteral 
epithelium. Bottom panel shows the ethidium bromide staining of 28  
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band in purified bovine (Fig. 4 a, lane 4) and mouse (Fig. 4 a,
lane 5) urothelial plaques. Immunoblot data showed that p35
and UPIII shared many properties: they have a 30-kD core
protein (Fig. 4, b and c); they were associated with the superfi-
cial umbrella cells of bovine urothelium (Fig. 4, d and e) and
with the suprabasal cells of mouse urothelium (Fig. 4, f and g;
Lin et al., 1995); and they were expressed in a differentiation-
dependent manner in cultured bovine urothelial cells (Fig. 4, h
and i). Finally, we found that p35 was enriched 
 
 
 
100-fold in
purified bovine urothelial plaques in comparison with the total
bovine urothelial protein extracts (Fig. 4 a). These results indi-
cated that p35 expression was urothelial-specific and differenti-
ation-dependent, and that p35 protein, like uroplakin III, was
urothelial plaque-associated (Figs. 1 a and 4 a).
 
Heterodimer formation between P35 and uroplakin Ib
 
Our recent transfection experiments supported the concept
that the four major uroplakins form two pairs consisting of
UPIa–UPII and UPIb–UPIII (Wu et al., 1995; Tu et al.,
2002). For example, we found that UPIII expressed alone in
293T cells was trapped in the ER; however, cotransfection of
UPIII with its putative partner UPIb (but not UPIa) resulted
in its release from the ER, allowing it to reach the cell surface
(Tu et al., 2002). This finding indicated that UPIII was a part-
ner of UPIb, and raised the question whether the UPIII-related
p35 might also partner with UPIb. To answer this question,
we cotransfected 293T cells with cDNAs of p35 and each of
the four uroplakins (Ia, Ib, II, and III). These experiments
were conducted using 293T cells, which could be easily trans-
fected and had no endogenous uroplakins, thus facilitating the
studies of heterodimer formation. Immunoprecipitation using
a p35 antibody established the coprecipitation of p35 with
UPIb, but not with other uroplakins (Fig. 5 a). In another ex-
periment, we assessed the glycosylation status of p35 in singly
(p35 alone) and doubly (p35 plus one uroplakin) transfected
293T cells. We found that p35, when expressed alone, was
synthesized as a 32-kD protein that was Endo H sensitive, in-
dicating that it harbored high mannose-type sugars (Fig. 5 b).
Cotransfection with UPIb, but not with other uroplakins, ren-
dered Endo H resistance to p35, confirming the ability of the
p35–UPIb complex to exit from the ER. Consistent with this
interpretation, our metabolic labeling experiment using dou-
ble-transfected 293T cells showed that p35 and uroplakin Ib
could be coprecipitated (by anti-p35 antibody) immediately
after a 10-min pulse labeling before p35 acquired Endo H re-
sistance, indicating that the formation of p35/UPIb het-
erodimer occurred in the ER (Fig. 5, c and d). Finally, immun-
ofluorescent staining of transfected 293T cells showed that
whereas singly expressed p35 was ER-associated (Fig. 6 a,
right) with no cell surface staining (Fig. 6 a, left), p35 ex-
pressed in the presence of uroplakin Ib was exposed on the sur-
face of living cells (Fig. 6 b and data not depicted).
 
Fig. 4 legend continued from previous page
 
and 18s ribosome RNA as a loading control. Note the differentiation-
dependent expression of both p35 and UPIII. (i) Immunofluorescent 
staining of cultured bovine urothelial cells (5-d pc, permeabilized and 
fixed with cold methanol/acetone) using an affinity-purified p35 anti-
body. Note the selective staining of superficial cells (*). Bars, 50 
 
 
 
m.
 
Figure 5.
 
Dimerization of p35 with uroplakin Ib, a partner of 
uroplakin III.
 
 (a) Human kidney 293T cells were cotransfected with 
cDNAs of p35 and one of the four uroplakins. Total cell lysates were 
treated with an antibody against p35, and the immunoprecipitates 
were immunoblotted with different uroplakin antibodies (top), or 
with anti-p35 (bottom). Lanes 1–3 show total cellular lysates (lane 1), 
immunoprecipitates from preimmune sera (lane 2), or from anti-p35 
(lane 3). Note the selective coprecipitation of p35 and UPIb. 
(b) 293T cells were transfected with p35 cDNA alone (lanes 1–3), or 
with p35 plus uroplakin Ib cDNAs (lanes 4–6). Total cellular proteins 
were isolated 24 h later, and immunoblotted using antibodies to 
p35 (top) or uroplakin Ib (bottom). The samples were either analyzed 
directly (lanes 1 and 4), after a 24-h incubation in a buffer (lanes 2 
and 5), or in a buffer containing endoglycosidase H (lanes 3 and 6). 
Note that p35, when transfected alone, was Endo H sensitive, but 
acquired Endo H resistance when cotransfected with uroplakin Ib. 
(c) 293T cells were transfected with p35 cDNA alone (lane 1), UPIb 
cDNA alone (lanes 2 and 3), or with both p35 and uroplakin Ib 
cDNA (lanes 4–13). Cells were pulse-labeled with [
 
35
 
S]methionine 
for 10 min and chased for various periods of time (marked in minutes 
on top). Immunoprecipitation (IP) was performed with preimmune 
serum (PI), anti-p35, or anti-UPIb antibodies as indicated. The 
precipitated products were analyzed by SDS-PAGE. The 
nonglycosylated (p35 or Ib) and glycosylated (p35* or Ib*) forms of 
the molecules are as marked. M denotes molecular mass markers 
(from top to bottom: 75, 50, 37, 25, and 20 kD). Note that the 
p35/UPIb heterodimer can be immunoprecipitated with anti-p35 
immediately after pulse labeling (lane 5). (d) Immunoprecipitates 
prepared from cells cotransfected with p35 and UPIIIb cDNAs (as in 
panel c) were either treated with endoglycosidase H (
 
 
 
) or incubated  
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Effects of uroplakin III ablation on p35 expression
 
The fact that UPIb could apparently form heterodimer with
both p35 and its closely related UPIII suggested that these
two molecules may perform similar functions. If so, one
might expect that genetic ablation of UPIII could lead to the
up-regulation of p35 as a compensatory mechanism. To test
this possibility, we studied the expression of p35 in UPIII-
deficient mice that we generated recently (Hu et al., 2000).
UPIII deficiency led to a coordinated change in the mRNA
and protein levels of uroplakins within the same “pair.” Thus,
within the UPIa/UPII pair, the mRNA of both uroplakins in-
creased approximately twofold, suggesting a coordinated up-
regulation and/or stabilization (Fig. 7 a). However, on the
protein level, these two uroplakins decreased 
 
 
 
20-fold in to-
tal cell lysates, suggesting lower translational efficiency and/or
degradation possibly due to suboptimal subunit stabilization
(Fig. 7 b). Within the putative p35/UPIb pair, both mRNAs
increased approximately sixfold (Fig. 7 a), whereas the pro-
 
overnight in a buffer without Endo H enzyme (
 
 
 
) as controls. M 
denotes molecular mass markers (from top to bottom: 37, 25, and 
20 kD). Note that the newly synthesized p35 were Endo H sensitive, 
but acquired Endo H resistance after 20–30 min when they entered 
into the Golgi. Although the amount of UPIb was a bit low in 
this experiment, this uroplakin never acquired Endo H resistance 
consistent with our earlier data (Tu et al., 2002).
Figure 6. Uroplakin Ib enables p35 to reach the cell surface. 
(a) 293T cells transfected with p35 cDNA alone were immunostained 
without ( P) or with ( P) saponin permeabilization. Note the 
inability of p35 to reach the cell surface. (b) 293T cells were 
cotransfected with p35 and HA-tagged UPIb cDNAs, and immuno-
stained using antibodies to p35 (green) and to the HA tag of UPIb 
(red), without ( P) or with saponin permeabilization ( P). Note the 
colocalization of p35 and UPIb in permeabilized cells, and the ability 
of p35 to reach the cell surface in the presence of UPIb.
Figure 7. Perturbed p35 expression in UPIII deficiency mice. 
(a) Northern analysis. Total RNAs from wild-type ( / ) and UPIII 
knockout ( / ) mouse bladders were resolved electrophoretically 
and probed with cDNA of mouse p35, uroplakins Ia, Ib, II, III, 
and GAPDH. Densitometry showed a five- to sixfold increase of 
p35 and UPIb messages in the  /  mice bladder, and an 
approximately twofold increase of UPIa and UPII messages. 
(b) Immunoblot analysis. Total urothelial proteins (20  g) from 
normal and uroplakin III–deficient mice were immunoblotted. 
Note that uroplakins Ia, Ib, and II were reduced 10–25 fold in the 
UPIII-deficient mouse bladder, whereas the p35 level was reduced 
by only threefold. (c) Immunohistochemical analysis. Paraffin 
sections of normal and UPIII-deficient bladders were immunostained 
with antibodies against p35, uroplakins Ia, Ib, II, III, and keratins 
(a mixture of AE1 and AE3 antibodies). Note the reduced 
expression of p35 and uroplakins Ia, Ib, and II in the hyperplastic 
uroplakin III-deficient urothelium. Also note the abnormal targeting 
of p35 (cytoplasmic accumulation) and UPIb (to basal lateral 
surface). Bar, 50  m. 
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teins decreased three- to 10-fold (Fig. 7 b), indicating that
p35 and UPIb were coordinately regulated. Immunohis-
tochemical staining results showed that although much of
UPIb was mistargeted to the basal–lateral surface (Hu et al.,
2000), small amounts of UPIb and p35 were associated with
the apical urothelial surface (Fig. 7 c; see Discussion).
 
Human p35 gene is localized on chromosome 7q11.23 
near the deleted region of the WBS
 
Human p35 gene was located on chromosome 7q11.23 with
six exons spanning 
 
 
 
5 kb (Fig. 8 a), which was 0.5 Mb cen-
tromeric to the PMSR6 gene. The sequence of p35 gene was
distally homologous with uroplakin III gene (Fig. 8 a), but
was highly related to PMSR6 gene that encoded a hypotheti-
cal DNA MMR enzyme-related protein (Horii et al., 1994;
Nicolaides et al., 1995). The close relationship between p35
and PMSR6 gene (Fig. 8 a) was indicated by the fact that (1)
a large stretch (
 
 
 
25 kb) of the 5
 
 
 
 upstream sequence of p35
gene was 
 
 
 
90% identical to the 5
 
 
 
 half of PMSR6 gene con-
taining its first 5 exons; (2) the p35 genomic sequence start-
ing from the first intron to the end of third intron was 
 
 
 
90%
identical to the sixth exon of PMSR6 and its surrounding in-
tron sequences; (3) the third exon of p35 gene, which corre-
sponded to exon 6 of the PMSR6 gene (Fig. 8 a, arrowhead),
encoded the 80 amino acid residues shared by these two pro-
teins (Fig. 2 b); and (4) the 3
 
 
 
 downstream sequence of p35
(
 
 
 
20 kb downstream from the sixth or last exon) was 
 
 
 
90%
identical to the 3
 
 
 
 downstream sequence of PMSR6 gene
(Fig. 8 b). Therefore, it seemed likely that p35 and PMSR6
genes were evolved by gene duplication (see Discussion);
given the more conserved and perhaps primitive nature of the
DNA MMR function, we speculate that PMSR6 gene was
the precursor of p35 gene. Southern analysis of human ge-
nomic DNA using a partial human p35 cDNA probe (corre-
sponding to the second and third exons of p35; a sequence
shared by the two genes) showed two equal intensity bands in
DNA digested by five different restriction enzymes, suggest-
ing the existence of two closely related genes (p35 and
PMSR6; Fig. 8 b). PCR products generated using primers
based on the second and third exons of p35 gene contained
the sequence of not only p35, but also that of PMSR6 (Fig. 8
c), thus confirming the close relationship between these two
genes. BLAST analysis of the HTGS database showed that
p35 and R6 genes are present in BAC clone RP11-340A14
and RP11-506L7, respectively. Based on Peoples et al.
(2000), Valero et al. (2000), and the HTGS-derived data,
these two clones are localized on chromosome 7q11.23 im-
mediately telomeric to HIP1, a single-copy gene that maps
telomeric to the frequent distal breakpoint of the WBS
(OMIM 194050; see Discussion and Fig. 8 d).
 
Discussion
 
An expanded uroplakin pair concept: uroplakins IIIa 
and IIIb (p35)
 
Here, we show that p35, a novel urothelial marker, is closely
related to uroplakin III in terms of the following: their core
protein size (Fig. 4, b and c); their transmembrane topology
(Figs. 2 and 9); their sequence homology (Fig. 2 b); their
sharing of a juxtamembrane sequence of 19 amino acids
(Fig. 2, b–d, and Fig. 9); their interaction with uroplakin Ib
in the ER (Fig. 5); and their urothelial specificity and differ-
entiation dependence (Figs. 3 and 4). Based on these simi-
larities, we propose to rename UPIII and p35 as uroplakins
IIIa and IIIb, respectively. As mentioned earlier, the four
known uroplakins can be separated into two pairs consisting
of UPIa/UPII and UPIb/UPIII according to the following
data: first, chemical cross-linking using bifunctional cross-
linking reagents of various length and hydrophobicity re-
sulted in the specific cross-linking of UPIa and UPIb to
UPII and UPIII, respectively (Wu et al., 1995). Second,
complexes of UPIa–UPII and UPIb–UPIII can be isolated
by ion exchanger chromatography from total uroplakins dis-
solved in octyl-glucoside (Liang et al., 2001). Third, the
Figure 8. Genomic structure of the human p35 gene. (a) The 
organization of human R6, p35, and uroplakin III genes. Note the 
extensive sequence homologies between p35 and R6 genes (thick 
bars) suggesting gene duplication. Arrowhead denotes an exon 
encoding the 80 amino acids shared by p35 and R6 proteins. 
(b) Southern blot. Human genomic DNA was digested with various 
restriction enzymes including BamHI (lane 1), EcoRI (lane 2), HindIII 
(lane 3), PstI (lane 4), and XbaI (lane 5). The DNA fragments were 
separated electrophoretically and hybridized with a partial human 
p35 cDNA (covering exons 2 and 3, a sequence shared by p35 and 
R6 genes). Note that at least two p35-related genomic fragments 
were detected in all digestions consistent with the existence of two 
independent genes, i.e., p35 and R6. (c) Two pairs of primers were 
used to amplify exons 2 and 3 of human p35 gene (an area highly 
homologous to intron 5 and exon 6 of the R6 gene), and the PCR 
products were sequenced. The two PCR products indeed contained 
the expected p35 (arrowhead) and R6 (arrow) genomic sequences 
(p35 sequence according to human cosmid RP11-340a14, and 
hPMSR6 to cosmid RP11-506L7), thus confirming the existence of 
the two highly related genes. (d) Location of human p35 and 
hPMSR6 genes on human chromosome 7 and their relation to the 
deletion region of the Williams-Beuren syndrome (open box). Dot, 
arrowhead, and vertical bars denote p35 gene, R6 gene, and other 
R6-related genomic loci, respectively. 
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knockout of mouse uroplakin III gene is accompanied by
the selective mistargeting of its putative partner, UPIb (Hu
et al., 2000). Our present in vitro transfection data indicate
that UPIb enables both UPIIIa and UPIIIb to exit from the
ER and to reach cell surface (Figs. 5 and 6; Tu et al., 2002),
thus broadening the pair concept to include UPIIIb which,
as a structural homologue of UPIIIa, can also partner with
UPIb (Fig. 9).
 
Dimerization of UPIIIb and Ib in ER
 
It is known that oligomerization of many membrane pro-
teins takes place in the ER, and that in most instances the
unassembled proteins are unable to exit from this compart-
ment (Reddy and Corley, 1998; Ellgaard et al., 1999;
Green, 1999). Our transfection experiments indicate that
UPIIIb, when expressed alone, is trapped in the ER (Fig. 6
a), and that UPIb, but not any other uroplakins, can rescue
UPIIIb, allowing it to exit from the ER and to reach the
cell surface (Fig. 6 b). This conclusion is supported by our
finding that the cotransfected UPIb converts the N-linked
oligosaccharides of UPIIIb from an Endo H–sensitive to an
Endo H–resistant form (Fig. 5 b), indicating that UPIb en-
ables UPIIIb to be processed by glycosylation enzymes that
are known to be associated with the medial compartment
of the Golgi apparatus. Immunoprecipitation studies using
metabolically labeled cells showed that UPIb and UPIIIb
can coprecipitate even before UPIIIb’s sugars acquire Endo
H resistance, indicating that heterodimer formation must
have occurred in the ER (Fig. 5, c and d). Finally, the fact
that antibodies to UPIIIb selectively pulled down UPIb in
metabolically labeled cells, without pulling down any other
labeled proteins, suggests that UPIIIb interacts directly
with UPIb without the participation of other proteins that
are present in the 293T cells (Fig. 5 c). Additional stud-
ies are needed to further elucidate how the UPIIIb/UPIb
and UPIIIa/UPIb heterodimers interact with the other
uroplakin pair (UPII/UPIa) to form a 16-nm particle, and
eventually to assembly into a two-dimensional crystal of
urothelial plaque.
 
Possible functions of UPIIIb
 
Existing data suggest that UPIIIb plays a urothelial-specific
function most likely involved in urothelial plaque formation.
First, UPIIIb is associated with the differentiated urothelial
cells (Fig. 3 and Fig. 4, d–i). Second, the amino acid se-
quences of human, mouse, and bovine UPIIIb are 
 
 
 
90%
identical (Fig. 2 a), suggesting that the protein plays a highly
conserved biological function. Third, the fact that UPIIIb is
highly enriched in purified bovine urothelial plaques sug-
gests that it is a plaque component (Fig. 4 a). Fourth, the rel-
atively large cytoplasmic domains of UPIIIb and UPIIIa sug-
gest these may mediate membrane–cytoskeletal interactions
serving to anchor the urothelial plaque to an underlying cy-
toskeletal network (Wu and Sun, 1993). The fact that UPI-
IIa and UPIIIb exhibit a much higher degree of homology in
their luminal domains (36%) than their cytoplasmic tails
(18%; Fig. 2 b) suggests that their conserved luminal do-
mains interact with a common target, i.e., UPIb, whereas
their cytoplasmic tails play chain-specific functions (Liang et
al., 1999). A potentially important difference between the
cytoplasmic tails of UPIIIa and UPIIIb is that only the
former harbors several potential phosphorylation sites (Wu
and Sun, 1993). Fifth, unlike UPIIIa that is present as a ma-
jor component in purified urothelial plaques, UPIIIb is
present at a much lower level amounting usually to 
 
 
 
10% of
UPIIIa (Fig. 1a and Fig. 4 a, lane 1) and this level is some-
what variable. Recently, we have shown by EM localization
that UPIIIa is associated with almost all urothelial plaques in
mouse and bovine urothelial umbrella cells (Liang et al.,
2001), suggesting that UPIIIa is a constant component of
both cytoplasmic and apical plaques. The low stoichiometry
of UPIIIb suggests that this protein is associated with a sub-
population of urothelial plaques, possibly conferring special
structural or functional properties to these plaques.
A puzzling phenotype of uroplakin III knockout mice is
the presence of some normal-looking (albeit much smaller)
urothelial plaques (0.05-
 
 
 
m-diam vs. 0.2–1-
 
 
 
m in normal
urothelium; Hu et al., 2000). There are two possible expla-
nations for this UPIIIa-independent plaque formation. One
is that the ablation of UPIIIa abolished the UPIIIa/UPIb
pair; but the remaining UPII/UPIa pair can still form small
urothelial plaques. Another possibility is that all four
uroplakins are required for plaque formation, but a small
amount of UPIIIa homologue, i.e., UPIIIb, can rescue some
of the other three uroplakins and is thus responsible for the
formation of the observed small plaques. Our current find-
ing that UPIIIb is up-regulated relative to other uroplakins
in the UPIIIa-deficient urothelium (Fig. 7, a and b) supports
the latter interpretation.
 
Possible significance of the CD 
and hPMSR6-related domains
 
It is interesting that UPIIIa and UPIIIb share 19 amino acid
residues (IDTWPGRRSGDMIIITSIL) located proximal to
their single transmembrane domain (Fig. 2, b and d). The
structural significance of this conserved domain (CD) is un-
clear, although our preliminary data indicate that mutations in
this domain do not affect UPIIIb–UPIb interaction in the ER
as assayed by cotransfection (unpublished data). Additional
Figure 9. Specificity of uroplakin heterodimer formation. A 
schematic diagram showing the specific interactions between 
uroplakins Ia and II, and uroplakin Ib with either IIIa or IIIb (p35). 
The gray and black thick bars denote the transmembrane domains 
and the 19-amino acid CD that is shared by UPIIIa and UPIIIb, 
respectively. The NH2-terminal 12 of the CD is also shared by UPII. 
Solid circles denote sugar moieties. L and C denote luminal and 
cytoplasmic side, respectively. 
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studies are needed to determine whether the CD plays a role
in subsequent steps of asymmetric unit membrane assembly.
A surprising feature of human UPIIIb protein is that it
contains a domain of 80 amino acid residues that are 
 
 
 
95%
identical to a portion of hPMSR6, a hypothetical DNA
MMR enzyme–related protein. That this hPMSR6-related
domain is a part of the UPIIIb molecule is supported by sev-
eral findings. First, the cDNA sequence of UPIIIb has been
validated by the fact that it can account for all five partial
protein sequences of electrophoretically purified p35 (Fig. 1
c), and that antibodies raised against several p35 peptide rec-
ognized the correct p35 protein (Fig. 4 a). Second, sequenc-
ing of a PCR product between the hPMSR6 and CDs con-
firmed the colinear existence of these two domains in a
single p35 cDNA. Third, the segment of 80 amino acids
that are shared by P35 and hPMSR6 is encoded by a single
exon (exon 2 of the p35 gene and exon 6 of the hPMSR6
gene; Fig. 8 a). Fourth, both human p35 and hPMSR6
genes are localized on chromosome 7q11.23, and the ge-
nomic structures of these two genes show striking conserva-
tions, suggesting the derivation of one from another by gene
duplication (Fig. 8 a).
Because little is known about the protein encoded by the
hPMSR6 gene, we do not know the functional significance
of the hPMSR6-related domain in UPIIIb. However, we do
know that because this domain is not present in UPIIIa, the
entire R6 domain is unlikely to be essential for p35 to form
heterodimer with UPIb. DNA MMR enzymes, including
hPMS2, play a key role in promoting genetic stability by re-
pairing DNA replication errors, inhibiting recombination
between nonidentical DNA sequences, and participating in
cellular responses to DNA damage (Modrich and Lahue,
1996; Harfe and Jinks-Robertson, 2000). Defects in hPMS2
have been shown to play a role in hereditary nonpolyposis
colon cancer (Nicolaides et al., 1994; Hamilton et al.,
1995). Moreover, ablation of mouse PMS2 gene leads to the
formation of sarcomas, lymphomas, and intestinal adenoma-
tous polyp (Baker et al., 1998). PCR amplification led to the
identification of 
 
 
 
17 human PMS2-related cDNAs, and
hPMSR6 is one of them (Horii et al., 1994; Nicolaides et
al., 1995). All these PMS2-related genes are mapped to
chromosome 7, are homologous with the 5
 
 
 
 portion of
PMS2, and contain several motifs highly conserved among
various DNA MMR enzymes, such as KELVEN and
GFRGEAL (Prolla et al., 1994), suggesting possible enzy-
matic domains. However, no data are as yet available about
the expression of hPMSR6 in terms of its tissue distribution
and protein function.
 
UPIIIb gene is telomeric of the frequently deleted 
region of the WBS
 
WBS is a neurodevelopmental disorder affecting multiple
organs with distinctive facial features, congenital cardiovas-
cular anomalies, mental retardation, growth deficiency, and
occasional infantile hypercalcemia. Importantly, WBS pa-
tients have an increased prevalence of urinary symptoms and
voiding dysfunctions (Babbitt et al., 1979; Morris et al.,
1990; Blane et al., 1994; Perez Jurado et al., 1996). For ex-
ample, Schulman et al. (1996) reported that 
 
 
 
10% of WBS
patients had bladder diverticula and uninhibited detrusor
contraction. Pankau et al. (1996) reported that 17.7% of the
WBS patients had bladder diverticula and renal abnormali-
ties. Other genitourinary manifestations include urethral
stenosis, vesicoureteral reflux, and recurrent urinary tract in-
fection (Lashkari et al., 1999). Stoermer et al. (1984) re-
ported that 12 out of 14 of children with all signs of WBS
had renal and lower urinary tract abnormalities, but only 1
out of 5 of children with only typical cardiovascular findings
(without pathognomonic faces or major mental retardation)
showed urinary tract problems. WBS is caused by the
heterozygous deletion of parts of chromosome subband
7q11.23 amounting to 1.5 to 2 Mb (Francke, 1999; Hock-
enhull et al., 1999; Peoples et al., 2000). Such deletions oc-
cur due to the presence of long stretches of duplicated se-
quences flanking this subband, thus facilitating inter- or
intra-chromosomal crossover events (Dutly and Schinzel,
1996; Urban et al., 1996; Baumer et al., 1998). Because p35
gene is localized near the telomeric duplicated sequence of
the WBS and because UPIIIa knockout led to widespread
anomalies in the lower urinary tract, including vesicoureteral
reflux (Hu et al., 2000), it is important to determine
whether p35 deletion plays a role in causing some of the ob-
served urinary tract defects in WBS.
Materials and methods
Bovine urothelial cDNA libraries
A bovine bladder–specific cDNA library was generated by suppression
subtractive hybridization using a PCR-Select cDNA Subtractive Kit (CLON-
TECH Laboratories, Inc.; Diatchenko et al., 1996; Deng et al., 2001).
Poly(A)
  mRNAs were isolated from bovine, mouse, and human bladder
using a PolyATtract
® mRNA isolation system (Promega). Bovine, mouse,
and human bladder cDNA libraries were constructed using a HybriZAP
2.1 XR library construction kit (Stratagene) and were screened using a par-
tial p35 cDNA. P35 phagemides of p35 were obtained by the in vivo exci-
sion of   phage DNA from all positive clones. DNA sequencing was per-
formed using the dideoxynucleotide chain termination method (Sanger et
al., 1977) with a DNA sequence kit (US Biochemical Corp.).
Mass spectrometry
The Coomassie blue–stained band was excised from the gel, and the pro-
tein was digested in-gel (Shevchenko et al., 1996). Digested peptides were
analyzed by LC/MS and LC/MS/MS on a mass spectrometer (API III ; MDS
Sciex) as described previously (Resing et al., 1993). De novo sequencing
was done manually, with a complete set of b and y ions observed for most
of the identified sequence.
RT-PCR and Northern and Southern blotting
Total RNAs from various tissues were isolated using an RNAgent
® system
(Promega). For Northern blotting, 10  g total RNA was electrophoretically
transferred onto a nylon membrane and hybridized with different 
32P-
labeled probes. For RT-PCR, cDNA was synthesized using a SuperScript™
first-strand synthesis system (GIBCO BRL). Primers for bovine p35 were
forward, 5 -CGTGCTTAGGGTGGGCAATG-3 , and reverse, 5 -ATCAT-
GTCTCCACTCCGCCG-3 . Primers for mouse p35 were forward, 5 -ACC-
TGGAAGGGAAGATCAC-3 , and reverse, 5 -AACGTTTTCCCATGAAG-
GAG-3 . 10  g of human blood genomic DNA was digested with various
restriction enzymes for 16 h, size-fractionated on an 0.8% agarose gel,
transferred to a nylon membrane, and probed with a 300-bp 5  end of hu-
man p35 cDNA (Lin et al., 1994).
Generation and purification of antibodies against synthetic peptides
Three peptides, (1) VLDRHSSAADTVW, (2) TNSRGSPQAETRWSD, and (3)
EPGLERFPSLSP were synthesized (Genemed Synthesis, Inc.) based on the
cDNA-deduced amino acid sequence of bovine p35. An additional cys-
teine residue was placed at the COOH terminus of peptide b and NH2 ter-
minus of peptides a and c. These peptides were conjugated to keyhole lim-
pet hemocyanin. 100  g of each conjugated peptide was used to prime
each rabbit and 50  g for booster injections at 2-wk intervals. AntibodiesUroplakin IIIb and urothelial differentiation | Deng et al. 693
were affinity-purified using a peptide-conjugated Ultralink Iodoacetyl col-
umn (Pierce Chemical Co.). The eluted antibodies were concentrated us-
ing Centricon-30 (Amicon).
Immunoblotting and enzymatic deglycosylation
Proteins were separated by SDS-PAGE on 17% polyacrylamide gels with an
acrylamide/bisacrylamide ratio of 120:1, and were electrophoretically trans-
ferred onto a nitrocellulose membrane. The membrane was briefly stained
with Fast Green (Sigma-Aldrich) to reveal protein bands. After blocking with
2% nonfat milk in PBS, the blots were incubated with specific primary anti-
bodies. The primary antibodies were detected with a goat anti–rabbit or
anti–mouse IgG conjugated with HRP (ICN Biomedicals). After washing
with PBS, the membrane was developed by the enhanced chemilumines-
cence Western blotting detecting system (Pierce Chemical Co.) and exposed
to Fuji x-ray film at RT. For enzymatic deglycosylation, bovine urothelial
plaques were solubilized in 0.5% SDS at RT for 15 min, and then incubated
with endoglycosidase H or with N-glycosidase F (Roche). Glycosidase was
omitted in negative control incubation. After incubation at 37 C for 16 h,
the reaction mixtures were resolved by SDS-PAGE and electrophoretically
transferred onto a nitrocellulose membrane. P35 was detected by immuno-
blotting using a peptide antibody against bovine p35.
Urothelial cell culture
Bovine urothelial cells were isolated from bovine bladder epithelial cells
and cultured in the presence of mitomycin C–treated NIH 3T3 feeder cells
in DME containing 15% FCS, 0.5  g/ml hydrocortisone, 5 ng/ml cholera
toxin, 5  g/ml insulin, and 15 ng/ml EGF as described previously (Surya et
al., 1990). 3T3 feeder cells and any contaminating fibroblasts were re-
moved by spraying the culture with 0.01% EDTA in PBS after the cell
reached  70% confluence. Urothelium were collected at different stages
of differentiation and stored at  70 C for further analysis.
Immunohistochemistry
Paraffin sections were treated with 1% hydrogen peroxide in methanol to
block the endogenous peroxidase, and incubated with normal 1:50 goat
serum in 2% BSA, followed by overnight incubation at 4 C with a peptide
antibody against bovine p35 and AU1, an mAb against UPIII (Liang et al.,
2001; Riedel et al., 2001). Primary antibodies were detected with specific
HRP-conjugated secondary antibodies (RCN). Preimmune serum and 2%
BSA were used as negative controls. After counterstaining with hematoxy-
lin, sections were mounted using glycerin gelatin and observed under a
Zeiss Axiophot microscope.
Transient transfection of 293T cells
cDNAs of all four uroplakins and p35 were isolated by PCR using bovine
urothelial cDNA as the template. Additional EcoRI and XhoI restriction
sites were introduced to the forward and reverse primers, respectively. The
cDNAs were cloned into the pcDNA3 vector using the EcoRI and XhoI
sites (Invitrogen). An HA tag was inserted into the small extracellular loop
region of the UPIb cDNA. 293T cells were maintained in DME supple-
mented with 10% FBS. The FuGENE6 reagent (Roche) was used for tran-
sient transfection. 18 h before transfection, 293T cells were plated in
6-well plates (6   10
5/well). cDNA was mixed with FuGENE6 (Roche; 1:3,
wt/vol) in serum-free DME, incubated at RT for 30 min, and added drop-
wise to the 293T cells. 24 h after transfection, cells were rinsed with ice-
cold PBS and lysed in lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl,
0.5% sodium deoxylcholate, 1% NP-40, 10  g/ml aprotinin, 10  g/ml leu-
peptin, and 1 mM PMSF) on ice. The total cell lysates were centrifuged at
13,000 g for 10 min at 4 C, and the supernatants were stored at  20 C or
used for experiments directly.
Metabolic labeling and immunoprecipitation
24 h after transfection, cells were rinsed twice with PBS prewarmed to
37 C and incubated for 30 min in a methionine-free DME containing 5%
dialyzed bovine serum. The cells were then pulse-labeled for 10 min with
[
35S]methionine (ICN Biomedicals) at 0.05 mCi/ml. Chase was done at
37 C for the indicated periods with DME containing an excess of unla-
beled methionine (30  g/ml). The labeled cells were washed with 4 C PBS
and extracted with lysis buffer for immunoprecipitation.
For immunoprecipitation, protein G–agarose beads (Roche) were pre-
conjugated with primary antibodies or preimmune serum for 2 h at 4 C.
After being precleaned with protein G–agarose beads, the supernatants of
total cell lysates were incubated overnight at 4 C, with gentle agitation,
with the antibody-conjugated protein G–agarose beads. The beads were
sedimented (5,000 g for 2 min) and washed four times with cold lysis
buffer. The antigens were then eluted with 0.2% SDS sample buffer.
Immunostaining
293T cells were plated on coverslips 24 h before transfection. 24 h after
transfection, the cells were fixed with 3% PFA in PBS, pH 7.5, and incu-
bated with 5% nonfat milk in PBS. Some cells were permeabilized by add-
ing 0.05% saponin to milk solution. The fixed cells were incubated at 37 C
for 90 min with a rabbit antibody against p35 (1:100) and a mouse mAb
against the HA tag of the UPIb, followed by a secondary antibody (1:200,
Texas red–conjugated donkey anti–mouse IgG and FITC-conjugated don-
key anti–rabbit IgG; Jackson ImmunoResearch Laboratories). Immuno-
stained cells were scanned using a confocal microscope (model LSM510;
Carl Zeiss MicroImaging, Inc.).
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